The efficacy of recombinant thrombomodulin in a patient with cholangitis with DIC

The efficacy of recombinant thrombomodulin in a patient with cholangitis with DIC - The efficacy of rTM in a patient with cholangitis with DIC

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018607

Enrollment

250

Registered

2015-08-09

Start date

2015-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cholangitis with DIC

Interventions

Duration:From september 1st, 2015 to September 31st, 2019 Drug: Recombinant thrombomodulin Times: 5 times generally Control group Duration:From september 1st, 2015 to September 31st, 2019 Drug: DI

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients with mild and moderate acute cholangitis (TG13) with DIC( Japanese Association for Acute Medicine-defined DIC criteria score>=4)

Exclusion criteria

Exclusion criteria: 1. The patients with hemorrhagic lesion. 2. The patients with allergy in rTM. 3. the pregnancy patients 4. Non imformed consent

Design outcomes

Primary

Measure	Time frame
Duration of DIC, DIC resolution rates	—

Secondary

Measure	Time frame
survival rate in 28 days	—

Countries

Japan

Contacts

Public ContactYusuke Suwa

Yokohama city university Depertment of gastroenterologicl surgery

yusuke_232002@yahoo.co.jp045-787-2650

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026